Merck's ROTATEQ(R) Reduced Hospitalizations and Emergency Department Visits Due to G9P1A(8) Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data

The prescribing information for Merck & Co., Inc.'s ROTATEQ(R) (rotavirus vaccine, live, oral pentavalent), the only vaccine in the U.S. to help prevent rotavirus gastroenteritis in infants and children caused by G1-G4 serotypes, now includes data showing that ROTATEQ reduced hospitalizations and emergency department visits caused by the G9P1A(8) rotavirus serotype, by 100 percent (zero cases were seen in those who received ROTATEQ compared with 14 cases in placebo recipients). These data are from a post-hoc analysis of healthcare utilization data from more than 68,000 infants in the Rotavirus Efficacy and Safety Trial (REST), one of the largest pre-licensure vaccine clinical trials ever...

Want to see the full article?

• Purchase this article for only $3.00